Buscar
Aytu Biopharma Inc
AYTUAñadir a la lista de seguimiento
2.160USD
+0.010+0.47%
Cierre 07/01, 16:00（ET）Cotizaciones retrasadas 15 min
23.18MCap. mercado
PérdidaP/E TTM
Más Datos de Aytu Biopharma Inc Compañía
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Información de Aytu Biopharma Inc
Símbolo de cotizaciónAYTU
Nombre de la empresaAytu Biopharma Inc
Fecha de salida a bolsaOct 20, 2017
Director ejecutivoDisbrow (Joshua R)
Número de empleados82
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 20
Dirección7900 E. Union Avenue
CiudadDENVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal80237
Teléfono17204376580
Sitio Webhttps://aytubio.com/
Símbolo de cotizaciónAYTU
Fecha de salida a bolsaOct 20, 2017
Director ejecutivoDisbrow (Joshua R)
Ejecutivos de Aytu Biopharma Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jarrett T. (Josh) Disbrow
Mr. Jarrett T. (Josh) Disbrow
Chief Business Officer
Chief Business Officer
61.57K
+52.15%
Mr. Ryan J. Selhorn, CPA
Mr. Ryan J. Selhorn, CPA
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
49.74K
+67.83%
Mr. Greg Pyszczymuka
Mr. Greg Pyszczymuka
Chief Commercial Officer
Chief Commercial Officer
36.10K
+34.05%
Mr. Carl C. Dockery
Mr. Carl C. Dockery
Independent Director
Independent Director
21.15K
+47.28%
Ms. Vivian H. Liu
Ms. Vivian H. Liu
Independent Director
Independent Director
19.82K
+50.44%
Mr. Joshua R. (Josh) Disbrow
Mr. Joshua R. (Josh) Disbrow
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. John A. Donofrio, Jr.
Mr. John A. Donofrio, Jr.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Abhinav (Abi) Jian
Mr. Abhinav (Abi) Jian
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jarrett T. (Josh) Disbrow
Mr. Jarrett T. (Josh) Disbrow
Chief Business Officer
Chief Business Officer
61.57K
+52.15%
Mr. Ryan J. Selhorn, CPA
Mr. Ryan J. Selhorn, CPA
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
49.74K
+67.83%
Mr. Greg Pyszczymuka
Mr. Greg Pyszczymuka
Chief Commercial Officer
Chief Commercial Officer
36.10K
+34.05%
Mr. Carl C. Dockery
Mr. Carl C. Dockery
Independent Director
Independent Director
21.15K
+47.28%
Ms. Vivian H. Liu
Ms. Vivian H. Liu
Independent Director
Independent Director
19.82K
+50.44%
Mr. Joshua R. (Josh) Disbrow
Mr. Joshua R. (Josh) Disbrow
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Aytu Biopharma Inc?
Los cinco principales accionistas de Aytu Biopharma Inc son: Mr. Jarrett T. (Josh) Disbrow
¿Cuántas instituciones poseen acciones de Aytu Biopharma Inc (AYTU)?
A fecha de 2026Q1, 69 instituciones poseen acciones de Aytu Biopharma Inc, con un valor de mercado combinado de aproximadamente 3.87M, lo que representa el 36.10% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -493525.00.
¿Cuál es la mayor fuente de ganancias de Aytu Biopharma Inc?
El 2026Q1, el segmento empresarial ADHD portfolio generó la ganancia más alta para Aytu Biopharma Inc, ascendiendo a 13.22M y representando el 87.15% de la ganancia total.